BMS-986226 / BMS - LARVOL DELTA

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=80 | Terminated | Sponsor: Bristol-Myers Squibb | Completed ➔ Terminated; Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.

Combination therapy • IO biomarker • Metastases • Trial termination • Oncology • Solid Tumor • ICOS

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=78 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed | N=234 ➔ 78 | Trial completion date: May 2023 ➔ Dec 2021 | Trial primary completion date: Oct 2022 ➔ Dec 2021

Combination therapy • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2; N=234; Active, not recruiting; Sponsor: Bristol-Myers Squibb; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed • Oncology • Solid Tumor

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2; N=234; Recruiting; Sponsor: Bristol-Myers Squibb; Trial completion date: Jan 2023 ➔ May 2023

Clinical • Combination therapy • Trial completion date

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2; N=277; Recruiting; Sponsor: Bristol-Myers Squibb; Trial completion date: Dec 2020 ➔ Jan 2023; Trial primary completion date: Apr 2020 ➔ Oct 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date